{
  "docId": "019de073-aaaa-768c-937f-f768840b87a6",
  "docSlug": "9b8664e841ca83938179aa04bf759b1d",
  "documentTitle": "BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides",
  "authorId": "brainstorm-cell-therapeutics",
  "authorName": "Brainstorm Cell Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 15,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a timeline-based process diagram to explain the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-aaaa-768c-937f-f768840b87a6/5",
  "deckHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6",
  "deckJsonHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6.json",
  "deckAnchorHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Designed to exclude slow progressors. Inclusion criteria specified: ALSFRS-R >= 25 at Screening Visit (Not at Baseline). Decline in ALSFRS-R total score of 3 or more points in the 12 weeks before randomization.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db5e4f7a-7ade-4eda-8232-f11eeffc5d4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Study timeline showing screening, randomization, treatment, and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d90a59de-305f-4e58-8427-a48edf39b057",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "Double-blind, Placebo-controlled, Randomized Trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f27cc23d-fa48-4d97-b805-d7c6c55ea9b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Cudkowicz, M, Lindborg S, Goyal N, et al. Musc Nerve, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3c3c429-269d-4ee6-830f-9f5a883d0d8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Phase 3 Trial Study Design: Designed to exclude slow progressors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cd35159-dfc0-4df3-ad6f-38394cda1d03",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "79e8be16-5cf0-4da5-827f-5f205e9f34d4",
      "evidence": "The timeline at the bottom of the slide represents the study phases as a Gantt-style schedule.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "5df98c18-fb13-4d4d-ab4a-82680e6de45e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 4-5 highlight the limitations of current treatments",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 3,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "bce1965c-83ec-40d6-9c4c-8bfd12826169",
      "evidence": "Slides 3 and 10 present before-after comparisons",
      "position": 0,
      "objective": "Show the effect of NurOwn treatment on biomarkers",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    },
    {
      "to": 5,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "35971733-2689-4bd5-878b-f418c33a2f7c",
      "evidence": "Slides 2-5 discuss the floor effect of the ALSFRS-R scale",
      "position": 1,
      "objective": "Highlight the limitations of current treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}